• Optimizing treatment of virus induced exacerbations of asthma in children using lysates of lactic acid bacteria Lactobacillus rhamnosus V
Come back

Optimizing treatment of virus induced exacerbations of asthma in children using lysates of lactic acid bacteria Lactobacillus rhamnosus V

SOVREMENNAYA PEDIATRIYA.2019.1(97):19-25; doi 10.15574/SP.2019.97.19

Shadrin O. G., Hayduchyk G. A., Sichel L.
SI «Institute of Pediatrics, Obstetrics and Gynecology named after academician O. Lukyanova of the National Academy of Medical Sciences of Ukraine», Kyiv
President of Pure Research Products, LLC, PhD; Boulder, Colorado, USA

Objective. To study the effectiveness of lactic acid lactic acid bacteria Lactobacillus rhamnosus V in children with virus-induced exacerbations of bronchial asthma.

Materials and methods. Were examined 35 patients aged 3 to 16 years old with exacerbation of bronchial asthma in the background of acute respiratory infections. Twenty five children of the main group were in the complex therapy of virus induced asthma exacerbation and were treated by lysate of the Lactic acid bacteria Lactobacillus rhamnosus V ( Del-Immune V®) at a dose of 25 mg 1 capsule 2 times a day 30 minutes before meals for 20 days. Ten patients were in the comparison group and obtained standard therapy. General clinical, immunological, allergic and statistical studies were used.

Results. Use of Del-Immune V® in the complex treatment of children with virus-nduced exacerbation of asthma, has led to a significant decrease in the frequency and severity of bronchial obstruction syndrome, which increases the effectiveness of treatment. In the main group, there was a significant increase in the concentration of IFN-gamma and a decrease in the concentration of cysteine leukotrienes in serum, and an increase in the concentration of a saliva IgA in the dynamics of treatment compared with the children in the comparison group.

Conclusions. Observed integrated therapeutic effect of Del-Immune V® use, no side effects and allergic reactions, justifying the appropriateness of Del-Immune V® inclusion in the complex therapy of virus-induced asthma exacerbations.

Key words: children, bronchial asthma, virus-induced phenotype, lysate of lactic acid bacteria Lactobacillus rhamnosus V, Del-Immune V®.

REFERENCES

1. Antypkin YuH, Lapshyn VF, Umanets TR. (2010). Klinichni nastanovy z diahnostyky ta likuvannia bronkhialnoi astmy u ditei. Zdorovia Ukrainy. 3(14): 39—41.

2. Belova OI. (2003). Kliniko-patogeneticheskoe znachenie nekotoryih tsitokinov (interleykin-4, 'gamma'-interferon) pri bronhialnoy astme u detey. Moskva: 27.

3. Kalyuzhin OV. (2012). Probiotiki kak sovremennyie sredstva ukrepleniya protivoinfektsionnoy zaschityi: mif ili realnost? Russkiy meditsinskiy zhurnal. 20(28): 1395—1401.

4. Kalyuzhin OV. (2013). Bezopasnost i fiziologichnost deystviya probiotikov kak sredstv immunokorrektsii. Rossiyskiy allergologicheskiy zhurnal. 3: 45—56.

5. Kalyuzhin OV. (2014). Ostryie respiratornyie virusnyie infektsii: sovremennyie vyizovyi, protivovirusnyiy otvet, immunoprofilaktika, immunoterapiya. Meditsinskie informatsionnyie tehnologii. Moskva: 40—43.

6. Klimenko VA i soavt. (2011). Virus-indutsirovannaya bronhialnaya astma u detey: sostoyanie problemyi i puti resheniya. Astma ta alerhiia. 4: 50—57.

7. Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry bronkhialnii astmi. (2013). Nakaz MOZ Ukrainy vid 08.10.2013 No.868. http://www.dec.gov.ua/mtd/_ba.html

8. Таточенко ВК. (2004). Острые респираторные заболевания у детей — антибиотики или иммуномодуляция. Вопросы современной педиатрии. 3; 2: 35.

9. Ursova NI. (2015). Immunologicheskaya funktsiya intestinalnoy mikrofloryi, ee narusheniya i vozmozhnosti korrektsii. Almanah klinicheskoy meditsinyi. 40: 35—47.

10. Feshchenko YuI, Ostrovskyi MM, Varunkiv OI. (2016). Bronkhialna astma, virus-indukovani zahostrennia: pohliad na problemu cherez pryzmu metabolizmu leikotriieniv. Ukr pulmonol zhurnal. 3: 59—63.

11. Coulombe F, Fiola S, Akira S, Cormier Y, Gosselin J. (2012). Muramyl dipeptide induces NOD2-dependent Ly6C(high) monocyte recruitment to the lungs and protects against influenza virus infection. PLoS One. 7(5): e36734. https://doi.org/10.1371/journal.pone.0036734; PMid:22590599 PMCid:PMC3348889

12. Fitzgerald KA. (2010). NLR-containing inflammasomes: Central mediators of host defense and inflammation. European Journal of Immunology. 40(3): 595—598. https://doi.org/10.1002/eji.201040331; PMid:20201007

13. Inohara N, Ogura Y, Fontalba A et al. (2003). Host recognition of bacterial muramyl dipeptide mediated through NOD2: Implications for Crohn's disease. J Biol Chem. 278(8): 5509—5512. https://doi.org/10.1074/jbc.C200673200; PMid:12514169

14. Jesenak М, Ciljakova M, Rennerova Z, Babusikova E, Banovcin P. (2014). Role of biofilm in children with recurrent upper respiratory tract infections. European Journal of Clinical Microbiology. 34: 38.

15. Kling S, Clare H, Donninger H, Milliams Z et al. (2005). Persistence of rhinovirus RNA after asthma exacerbation in children. Clin Exp Allergy. 35(5): 672—678. https://doi.org/10.1111/j.1365-2222.2005.02244.x; PMid:15898992

16. Mohapatra S. (2008). Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev. 21; 3: 495—504. https://doi.org/10.1128/CMR.00054-07; PMid:18625684 PMCid:PMC2493089

17. Montuschi P. (2010). Role of Leukotrienes and Leukotriene Modifiers in Asthma Pharmaceuticals. Therapeutic Advances in Chronic Disease. 3(6): 1792—1811.

18. Nafstad P, Clare A Skrondal, Nystad Р. (2005). Еarly Respiratory Infections, Asthma, and Allergy: 10-Year Follow-up of the Oslo Birth Cohort Brunekreef Bert. Pediatrics. 116; 2: e255-e262. https://doi.org/10.1542/peds.2004-2785; PMid:16061578

19. Xatzipsalti M, Clare F Psarros, Konstantinou G et al. (2007). Modulation of the epithelial inflammatory response to rhinovirus in an atopic environment. Contrib Microbiol. 14: 33—41. https://doi.org/10.1159/000107053; PMid:17684331

Article received: Oct 08, 2018. Accepted for publication: Feb 11, 2019.